bisoprolol / Generic mfg. - LARVOL DELTA

Cardioprotection without risk? meta-analysis of prophylactic agents in low-risk cancer patients on anthracyclines (ASH 2025) - "We included randomized controlled trials (RCTs) of prophylactic ACE inhibitors, ARBs, beta-blockers, statins, dexrazoxane, or SGLT2 inhibitors in adults without pre-existing cardiovascular risk factors...Agents studied included beta-blockers (nebivolol, carvedilol, bisoprolol), ACE inhibitors (ramipril), ARBs (telmisartan), and spironolactone. Treatment duration ranged from 4 months to 1 year; anthracycline doses reached up to 689 mg/m² (epirubicin) or 536 mg/m² (doxorubicin)...The protective benefit was greater in contexts involving higher cumulative anthracycline doses and concurrent cardiotoxic therapies such as trastuzumab...However, high heterogeneity limits firm conclusions. Given the moderate effect size and heterogeneity, further large-scale, well-formulated trials are essential to identify optimal cardioprotective agents and precise patient selection criteria."

Retrospective data • Breast Cancer • Congestive Heart Failure • Heart Failure • Oncology • Solid Tumor

Risk Factors for Drug-Induced Severe Cutaneous Adverse Reactions: A Real-World Pharmacovigilance Analysis. (PubMed, J Dermatol) - "Logistic regression identified older age, male sex, and 114 drugs as independent risk factors for drug-induced SCARs, including amlodipine (adjusted ROR = 2.89), bisoprolol (adjusted ROR = 3.52), and losartan (adjusted ROR = 2.77). In the non-Asian population, the strongest signals were observed for allopurinol (adjusted ROR = 98.52), cefotaxime (adjusted ROR = 68.52), and lamotrigine (adjusted ROR = 38.59), whereas apalutamide (adjusted ROR = 14.57), ipilimumab (adjusted ROR = 3.24), and acetylsalicylic acid (adjusted ROR = 2.85) were detected only in Asians...The Asian population had a significantly shorter TTO compared to the non-Asian population (p < 0.001). This study uses FAERS data to analyze risk factors for drug-induced SCARs, emphasizing early identification and discontinuation of suspected drugs to enhance patient safety."

Adverse events • Journal • Real-world evidence • Immunology

Point-of-Care Agitated Saline Contrast Echocardiography in the Diagnosis of Respiratory Failure: A Case of Hepatopulmonary Syndrome With Decompensated Heart Failure. (PubMed, Cureus) - "Past medical history was notable for dilated alcoholic cardiomyopathy, heart failure with reduced ejection fraction (New York Heart Association (NYHA) class II, left ventricle ejection fraction (LVEF) 30%), permanent atrial fibrillation (AF) (on bisoprolol and anticoagulation with acenocoumarol), and a prior mitral valve prosthesis...However, despite high-flow nasal oxygen therapy, subsequent noninvasive ventilation(NIV) (fraction of inspired oxygen (FiO₂) 1.0), and pharmacologic therapy with furosemide resulting in satisfactory diuresis (250 mL/h) and reduced pulmonary congestion on lung ultrasound, oxygenation improved only minimally (PaO₂ up to 40 mmHg), and dyspnea persisted.  Given the presence of cirrhosis with portal hypertension and refractory hypoxemia, and that a workup for HPS had not yet been performed, a bedside agitated-saline contrast echocardiography was performed at the point of care. Microbubbles appeared in the left atrium (LA) and..."

Journal • Addiction (Opioid and Alcohol) • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Gastroenterology • Heart Failure • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Portal Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Transplantation

Acute Supraventricular Tachycardia Revealing a Massive Saddle Pulmonary Embolism in a Young Male With Rhinovirus Infection: A Case Report. (PubMed, Cureus) - "During admission, he developed recurrent and refractory episodes of SVT, ultimately necessitating systemic thrombolysis with intravenous alteplase. Arrhythmia control was achieved with digoxin and bisoprolol, and follow-up echocardiography showed normalization of right ventricular function...This case highlights SVT as a rare but clinically significant presentation of acute PE, underscoring the importance of considering PE in patients with new-onset tachyarrhythmias and hemodynamic compromise. Early recognition and timely management are critical to preventing morbidity and mortality in such presentations."

Journal • Cardiovascular • Infectious Disease • Pulmonary Embolism • Respiratory Diseases • Venous Thromboembolism • Ventricular Tachycardia

Orbital pain beyond the acute phase: A long-term manifestation of carotid dissection (EHF-EHC 2025) - "She was managed with clopidogrel, atorvastatin and antihypertensive therapy.Cardiology follow-up revealed frequent symptomatic ventricular extrasystoles, treated with bisoprolol and flecainide...Low-dose amitriptyline was initiated, with partial symptomatic relief...Multidisciplinary assessment was essential to exclude recurrence or structural complications. This case highlights the need for long-term follow-up and individualised pain management beyond radiological resolution."

Cardiovascular • Hypertension • Musculoskeletal Pain • Pain • Rheumatology

Sustained Intraocular Pressure Reduction Using Bisoprolol-Loaded PLGA Nanoparticles: A Promising Strategy for Enhanced Ocular Delivery with Reduced GFAP Expression Indicative of Lower Glial Activation. (PubMed, Pharmaceutics) - "Quantitative immunohistochemistry showed lower retinal GFAP expression with BSP-PLGA-NPs compared with induced controls and drug solution, which is indicative of attenuated glial activation. These data support improved ocular delivery and an improved pharmacodynamic effect; however, they demonstrate association rather than a direct mechanistic suppression of glial pathways."

Journal • CNS Disorders • Glaucoma • Ophthalmology • FAP • GFAP

A pilot study of re-purposing drugs to treat koalas with chlamydia. (PubMed, Sci Rep) - "One lead, bisoprolol fumarate, showed an impact on chlamydial infection and burden in vitro and in vivo. Whilst the mechanism of action may not support progressing this lead further, the approach to screening the library and list of candidates may enable identification of other new koala treatments. This study demonstrates the potential to apply drug re-purposing to koala treatment and presents a list of candidates that could be explored further."

Journal • Infectious Disease

A case report of blood pressure fluctuation, inverted Takotsubo cardiomyopathy, and pulmonary embolism: searching for a link. (PubMed, Eur Heart J Case Rep) - "Perioperative administration of oral doxazosin and bisoprolol allowed a successful laparoscopic right adrenalectomy after 3-month anticoagulation. Despite the lack of established recommendations for managing BP and HR fluctuations in patients with Pheo, the coexistence of PE further complicates the clinical management of this condition, suddenly modifying the haemodynamic status and increasing the risk of major bleeding events from the neoplastic mass. Patients presenting with ITC, PE, and Pheo require a multidisciplinary approach involving a cardiologist, hypertension specialist, and surgeon to resolve this intriguing clinical condition."

Journal • Cardiomyopathy • Cardiovascular • Hypertension • Hypotension • Oncology • Pain • Pulmonary Embolism • Respiratory Diseases • Solid Tumor

Impact of β-Blocker Nebivolol versus Bisoprolol Prescription at Discharge on Long-term Clinical Outcomes in ST elevation Myocardial Infarction Patients with Reduced Left Ventricular Ejection Fraction ( (AHA 2025) - "In STEMI patients with reduced LVEF treated with DESs, discharge prescription of Nebivolol was associated with a significantly lower incidence of MACE compared to Bisoprolol, while total death remained similar between the two groups after IPTW adjustment. These findings suggest that Nebivolol may offer additional benefits in reducing MACE in this population."

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

Deglutition-Induced Atrial Fibrillation in a Previously Healthy Adult Male: A Rare Trigger Unmasked After Medication Discontinuation. (PubMed, Cureus) - "Initially diagnosed with paroxysmal AF and successfully managed on flecainide and bisoprolol, the patient became asymptomatic, and his Holter monitor prior to the latest admission showed he maintained sinus rhythm. Investigations ruled out structural heart disease, thyroid dysfunction, and electrolyte abnormalities. This case highlights the importance of recognizing atypical triggers of AF."

Journal • Atrial Fibrillation • Cardiovascular • Endocrine Disorders • Heart Failure

Synthesis of β-Cyclodextrin-Calix[4]arene Polymer-Based Chiral Stationary Phase for Chromatographic Separation of Enantiomers. (PubMed, Chirality) - "Compared with the home-made β-cyclodextrin-based chiral column, the prepared β-cyclodextrin-calix[4]arene polymer-based chiral column showed superior enantioseparation performance toward 1-phenylethanol, prothioconazole, promethazine, propranolol, and bisoprolol. These chiral compounds can be separated within 10 min under reversed-phase mode with resolutions ranging from 1.62 to 1.80. These findings will provide an important reference for developing novel supramolecule-based chiral stationary phases."

Journal

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol (clinicaltrials.gov) - P=N/A | N=817337 | Completed | Sponsor: Brigham and Women's Hospital | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • Cardiovascular • CNS Disorders • Hypertension

Beta-Blocker Therapy After Myocardial Infarction in Patients with Preserved Left Ventricular Ejection Fraction: An Individual Patient Data Meta-Analysis of Randomized Controlled Trials (AHA 2025) - "Bisoprolol was used in 49.1%, metoprolol in 46.8%, and carvedilol in 4.8%. A primary endpoint event occurred in 1447 (8.3%).The results will be presented at the AHA congress upon acceptance.Conclusion This IPD meta-analysis aims to provide a definite answer of whether beta-blocker therapy in patients with a recent MI and preserved LVEF reduces clinical events."

Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Ventricular Tachycardia

The Beta-Blocker Chronicle: From Past Principles to Present Practice - Implications for the Indian Subcontinent. (PubMed, Indian Heart J) - "Among contemporary agents, bisoprolol and nebivolol exemplify next generation β-blockers with high β1-selectivity, favourable tolerability, and cardioprotective effects beyond blood pressure and heart rate control. In Indian context, prescribing trends highlight bisoprolol among the most prescribed β-blockers, reflecting its clinical trust and relevance. Regional experiences affirm the value of β-blockers in optimizing cardiovascular outcomes across the Indian subcontinent."

Journal • Review • Asthma • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Heart Failure • Hypertension • Immunology • Metabolic Disorders • Myocardial Infarction • Nephrology • Pulmonary Disease • Renal Disease • Respiratory Diseases

Prescription Drug Coverage of Guideline-Directed Medical Therapy for People Living with Heart Failure with Reduced Ejection Fraction in Canada. (PubMed, CJC Open) - "In all provincial and territorial plans, patient eligibility and prior medication use criteria are required for sacubitril-valsartan reimbursement...Carvedilol coverage is not a benefit in Ontario or British Columbia. Bisoprolol and spironolactone have universal coverage. Eplerenone is not listed in British Columbia. Dapagliflozin coverage is a benefit in all plans except Quebec. Ivabradine coverage has patient eligibility and prior medication use criteria in all provinces and territories and prescriber restrictions in certain regions...Coverage criteria include prior medication use and prescriber qualifications, which are not supported by evidence-based guidelines. Systemwide changes in the funding of drug reimbursement programs are needed to improve access to GDMT for the more than 750,000 people living with HF in Canada."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Factors Influencing Internal Medicine Resident Beta-Blocker Discontinuation in Acute Decompensated Heart Failure. (PubMed, CJC Open) - "In scenario 2, 74% of participants initiated metoprolol succinate, 25% chose carvedilol, and only 1 participant chose bisoprolol. Drivers of inpatient beta blocker discontinuation should be considered by internal medicine training programs and heart failure guideline writers when opportunities arise to enact practice changes that align with evidence."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Late-Onset Donor-Derived Hypertrophic Cardiomyopathy Following Orthotopic Heart Transplant (AHA 2025) - "She was started on bisoprolol 2.5 mg, with improvement in 5 months...Tacrolimus was tapered in favor of sirolimus.Reasoning:Imaging is consistent with the apical variant of HCM...This case illustrates a rare but likely underrecognized form of late-onset allograft dysfunction. Though uncommon, donor-derived genetic cardiomyopathies should be considered in HT patients with unexplained LVH, as this may warrant a significant change to the post-HT immunosuppressive regimen."

Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Hypertension • Hypertrophic Cardiomyopathy • Immunology • Infectious Disease • Pulmonary Disease • Transplantation • TGFB1

One-Year Outcomes of Bisoprolol vs Metoprolol Succinate in Patients with Heart failure with reduced ejection fraction and End Stage Kidney Disease: A Propensity-Matched Study (AHA 2025) - "In this real-world, propensity-matched cohort of patients with HFrEF and ESRD, bisoprolol was associated with lower 1-year mortality compared with metoprolol succinate, but had comparable MACE and Hospitalization rates. These findings suggest bisoprolol may offer a survival benefit in this high-risk population and merit further prospective evaluation."

Clinical • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Nephrology • Renal Disease

Guideline-Directed Medical Therapy Prescribing Trends in Patients with Heart Failure with Preserved Ejection Fraction: A Nationwide Analysis (AHA 2025) - "Trends in prescribing of SGLT2i, MRAs, GLP-1 RAs (semaglutide and tirzepatide), ARNIs, ACEi/ARBs, and BBs (metoprolol succinate, carvedilol, bisoprolol) from 2017 to 2024 were analyzed in the overall HFpEF population and subgroups with obesity, DM, CV disease (AF/flutter, CAD, HTN), CKD, and by sex.ResultsWe identified 940,185 patients with HFpEF from 2017 to 2024 [mean age 75 ± 13 yrs, 56.3% female, 79.2% white, 4.7% Hispanic, mean BMI 34.2 ± 5.1 kg/m2]. (Figure/Table 1).ConclusionsAlthough prescription trends have improved, the use of SGLT2i, MRAs, GLP-1 RAs and ARNI (in females) remains suboptimal in patients with HFpEF, with prescribing decisions largely influenced by associated comorbidities. Further clinician awareness of the latest evidence-based management strategies for HFpEF is essential."

Clinical • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Genetic Disorders • Heart Failure • Obesity

Exercise Response to Bisoprolol and Verapamil treatment in Non-Obstructive Hypertrophic Cardiomyopathy (AHA 2025) - "Resting VO2 was unchanged. Verapamil reduced resting HR (-6 min-1, p<0.001), diastolic BP (-5 mmHg, p=0.010), RPP (-1212 min-1× mmHg, p<0.001), but resting systolic BP, VO2 and O2-pulse were unchanged.ConclusionBisoprolol significantly reduced oxygen consumption and estimates of myocardial work at peak exercise compared to placebo, while verapamil did not affect these markers significantly compared to placebo."

Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy • Ventricular Tachycardia

A multicenter, randomized, double-blind, double-dummy, placebo-controlled, position-controlled, fixed-dose combination dose exploration, parallel-designed Phase II clinical trial of levamlodipine besylate and bisoprolol fumarate for the treatment of mild to moderate essential hypertension (ChiCTR) - P2 | N=400 | Completed | Sponsor: Peking University People's Hospital; Shihuida Pharmaceutical Group (Jilin) Ltd.

New P2 trial • Cardiovascular • Hypertension

Eco-friendly micellar HPLC for metformin and bisoprolol analysis in diverse matrices with a green and blueness perspective on drug purity and safety. (PubMed, Sci Rep) - "The established method epitomizes accuracy, cost-effectiveness, selectivity, and reproducibility. The evaluation of the suggested approaches' level of greenness was meticulously conducted using a variety of assessments, including the Analytical eco-scale system, the Modified Green Analytical Procedure Index (MoGAPI), The Analytical Green Star Area (AGSA), Blueness evaluation using BAGI tools, Carbon footprint (CaFRI), Click Analytical Chemistry Index (CACI) and White analytical chemistry (WAC)."

Journal • Cardiovascular • Hypertension

The secretome released by IFN-γ-primed cardioesphere-derived cells as a therapeutic alternative in the treatment of myocardial infarction. (ESGCT 2024) - "To assess the impact of secretome from primed CDCs (S-pCDCs) on MI treatment, we conducted an in silico analysis focusing on the efficacy of specific medications, including Captopril (antihypertensive), Bisoprolol (antihypertensive), and Spironolactone (beta-blocker). This analysis suggest that the treatment with S-pCDCs could mimic the effects of Captopril and Spironolactone, simplifying MI treatment. However, further validation studies are required to confirm these findings."

Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • IFNG

Ivabradine Versus Up-titrated Bisoprolol for Persistent Tachycardia After Primary PCI in Anterior STEMI: A Single-center, Open-label, Pragmatic RCT. (PubMed, Cardiovasc Drugs Ther) - "In anterior-STEMI patients restricted by β-blocker ceiling, ivabradine add-on safely achieves sustained heart-rate reduction and early ventricular recovery without affecting 12-month MACE. Larger, blinded trials are warranted to confirm long-term efficacy and cost-effectiveness."

Journal • Cardiovascular • Hypotension • Myocardial Infarction

A combination strategy of HPLC and boric acid modified β-CD polymer for super-efficiently separating chiral substances with O/N atoms in chiral and/or adjacent carbons. (PubMed, Anal Chim Acta) - "Typical cases included bisoprolol (Rs = 48.19), propranolol (Rs = 45.50), chlorpheniramine (Rs = 38.36), and metoprolol (Rs = 20.26). The synergistic mechanism offers strong and specific recognition toward chiral substances with O/N atoms in chiral and/or adjacent carbons. This approach represents a novel strategy for efficient and economical HPLC-based enantioseparation using widely accessible materials and methods."

Journal